VivoSim Labs, INC.(VIVS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,779 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
VIVS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for VivoSim Labs, INC. (VIVS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VIVS at 13.5/100 on a 32-signal composite quality model, placing it at rank #2,779 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.1) and balance sheet strength (0.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), VivoSim Labs, INC. reports quarterly revenue of $40.0K, net income of $-5.8M, free cash flow of $-2.2M. Top institutional holders of VIVS by reported 13-F value include GEODE CAPITAL MANAGEMENT,, GOLDMAN SACHS GROUP, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. VIVS trades on the Nasdaq exchange and files with the SEC under CIK 1497253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VIVS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VivoSim Labs, INC. directly from SEC EDGAR.
Revenue
Q4 2026
$40.0K
Net Income
Q4 2026
$-5.8M
Free Cash Flow
Q4 2026
$-2.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-9.0% YoYNet Income
-456.4% YoYOperating Income
+8.9% YoYEPS (Diluted)
-214.7% YoYTotal Assets
-49.6% YoYOp. Cash Flow
-14.4% YoY| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $131.0K -9.0% | $144.0K +32.1% | $109.0K -70.5% | $370.0K -75.3% | $1.5M | $0.00 |
| Net Income | $-13.8M -456.4% | $-2.5M +83.0% | $-14.7M +15.0% | $-17.3M -50.8% | $-11.4M +32.0% | $-16.8M |
| Operating Income | $-11.5M +8.9% | $-12.6M +16.4% | $-15.1M +14.9% | $-17.7M -54.5% | $-11.5M +31.8% | $-16.8M |
| EPS (Diluted) | $-5.35 -214.7% | $-1.70 -50.1% | $-1.13 -872.0% | $-0.12 -50.1% | $-0.08 | — |
| Total Assets | $7.4M -49.6% | $14.7M +130.7% | $6.3M -68.7% | $20.3M -39.0% | $33.3M -16.6% | $39.9M |
| Operating Cash Flow | $-10.8M -14.4% | $-9.5M +35.4% | $-14.7M -18.1% | $-12.4M -46.8% | $-8.5M +36.6% | $-13.3M |
Get alerted when VIVS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for VivoSim Labs, INC. including:
Top Institutional Holders of VIVS
GEODE CAPITAL MANAGEMENT, LLC
$52.7K36,850 shGOLDMAN SACHS GROUP INC
$23.0K16,072 shVANGUARD CAPITAL MANAGEMENT LLC
$22.0K15,371 shBlackRock, Inc.
$16.9K11,817 shVANGUARD FIDUCIARY TRUST CO
$10.0K7,003 shCITIGROUP INC
$9.3K6,504 shTower Research Capital LLC (TRC)
$3.3K2,308 shUBS Group AG
$1.4K952 shSBI Securities Co., Ltd.
$316.00221 shAllworth Financial LP
$298.00208 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $52.7K | 36,850 |
| GOLDMAN SACHS GROUP INC | $23.0K | 16,072 |
| VANGUARD CAPITAL MANAGEMENT LLC | $22.0K | 15,371 |
| BlackRock, Inc. | $16.9K | 11,817 |
| VANGUARD FIDUCIARY TRUST CO | $10.0K | 7,003 |
| CITIGROUP INC | $9.3K | 6,504 |
| Tower Research Capital LLC (TRC) | $3.3K | 2,308 |
| UBS Group AG | $1.4K | 952 |
| SBI Securities Co., Ltd. | $316.00 | 221 |
| Allworth Financial LP | $298.00 | 208 |
More Healthcare Companies
View all Healthcare →Put VIVS on your watchlist
Track score changes the day VivoSim Labs, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VIVS a good stock to buy?
13F Pro's AI-powered analysis of VivoSim Labs, INC. (VIVS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VIVS are available on the VIVS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own VIVS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VIVS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VivoSim Labs, INC.'s investment landscape.